When conjunctival lymphoma extends beyond the eye to involve other sites in the body, systemic treatment decisions become central. The extent of disease — whether localised or disseminated — is the primary determinant of the therapeutic approach.
This protocol covers conjunctival lymphoma that has disseminated to other parts of the body. Individual treatment is determined by whether the tumour is localised to the conjunctiva or disseminated beyond it.
There is no universally accepted gold standard for disseminated conjunctival lymphoma. The approach involves systemic agents — including both chemotherapy and immunotherapy options, and combination regimens — selected according to the individual patient. The complete evidence-based protocol is available via the link below.
Individual treatment is determined by whether the tumor is localized to the conjunctiva or disseminated to other parts of the body.
There is no universally accepted gold standard of treatment for disseminated disease.
A number of single agents (including chemotherapy and immunotherapy) as well as combination chemotherapy regimens are commonly used.
View source ↗